AstraZeneca struck out in May in trying to expand severe eosinophilic asthma drug Fasenra into COPD. But it does have new long-term data that could bolster the drug in its current indication.
Boehringer Ingelheim has expanded access to its digital adherence programme that helps COPD patients take their medicines as prescribed by offering educational and motivational tools.